For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the emergence of Tafamidis and Tafamidis meglumine represents a true breakthrough . These novel therapies preserve the transthyretin protein, preventing its destructive build-up and reducing the impact of the illness. Individuals are now reporting b